ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA

 
• By Joseph Haas
  
Apples to apples
Icer's reviewed two NASH drug candidates ahead of potential approval • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip